NO20006431L - Sammensetning for å forhindre og/eller behandle osteoporose og forandringer på grunn av menopausalsyndrom - Google Patents

Sammensetning for å forhindre og/eller behandle osteoporose og forandringer på grunn av menopausalsyndrom

Info

Publication number
NO20006431L
NO20006431L NO20006431A NO20006431A NO20006431L NO 20006431 L NO20006431 L NO 20006431L NO 20006431 A NO20006431 A NO 20006431A NO 20006431 A NO20006431 A NO 20006431A NO 20006431 L NO20006431 L NO 20006431L
Authority
NO
Norway
Prior art keywords
composition
prevent
menopausal syndrome
changes due
treat osteoporosis
Prior art date
Application number
NO20006431A
Other languages
English (en)
Norwegian (no)
Other versions
NO20006431D0 (no
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Publication of NO20006431D0 publication Critical patent/NO20006431D0/no
Publication of NO20006431L publication Critical patent/NO20006431L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
NO20006431A 1998-06-23 2000-12-15 Sammensetning for å forhindre og/eller behandle osteoporose og forandringer på grunn av menopausalsyndrom NO20006431L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT98RM000417A IT1299191B1 (it) 1998-06-23 1998-06-23 Composizione atta a prevenire e trattare l'osteoporosi e le alterazioni legate alla menopausa
PCT/IT1999/000174 WO1999066913A2 (en) 1998-06-23 1999-06-17 Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome, comprising propionyl-l-carnitine and genistein

Publications (2)

Publication Number Publication Date
NO20006431D0 NO20006431D0 (no) 2000-12-15
NO20006431L true NO20006431L (no) 2001-02-22

Family

ID=11406005

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006431A NO20006431L (no) 1998-06-23 2000-12-15 Sammensetning for å forhindre og/eller behandle osteoporose og forandringer på grunn av menopausalsyndrom

Country Status (27)

Country Link
US (1) US6335038B1 (is)
EP (1) EP1089742B1 (is)
JP (1) JP4430233B2 (is)
KR (1) KR20010071541A (is)
CN (1) CN1306434A (is)
AR (1) AR018924A1 (is)
AT (1) ATE228367T1 (is)
AU (1) AU755272B2 (is)
BR (1) BR9911440A (is)
CA (1) CA2334875C (is)
DE (1) DE69904172T2 (is)
DK (1) DK1089742T3 (is)
EE (1) EE200000741A (is)
ES (1) ES2188177T3 (is)
HU (1) HU224957B1 (is)
IL (1) IL140163A0 (is)
IS (1) IS5764A (is)
IT (1) IT1299191B1 (is)
MA (1) MA26655A1 (is)
NO (1) NO20006431L (is)
NZ (1) NZ508877A (is)
PL (1) PL192118B1 (is)
PT (1) PT1089742E (is)
SK (1) SK19292000A3 (is)
TN (1) TNSN99132A1 (is)
TR (1) TR200003735T2 (is)
WO (1) WO1999066913A2 (is)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1302863B1 (it) * 1998-11-13 2000-10-10 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante e preventiva di alterazionitrombotiche e aterosclerotiche comprendente una carnitina ed un
US6476010B2 (en) * 2000-03-10 2002-11-05 Hill's Pet Nutrition Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals
US20010039296A1 (en) * 2000-03-23 2001-11-08 Debasis Bagchi Method and composition for preventing or reducing the symptoms of menopause
US20020076470A1 (en) 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
US8669282B2 (en) 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
IT1317079B1 (it) 2000-12-21 2003-05-26 Sigma Tau Ind Farmaceuti Uso della isovaleril l-carnitina per la preparazione di un medicamentoper la prevenzione e cura dell'osteoporosi.
BR0207948A (pt) * 2001-03-09 2004-07-27 Produits Nestel S A Soc D Composição que melhora os déficits fisiológicos relacionados com a idade e que aumenta a longevidade
ATE367810T1 (de) * 2001-03-15 2007-08-15 Dsm Ip Assets Bv Zusammensetzung zur prävention von osteoporose bestehend aus einer kombination aus isoflavonen und polyungesättigten fettsäuren
AUPR957001A0 (en) * 2001-12-19 2002-01-24 Novogen Research Pty Ltd Isoflavone conjugates, derivatives thereof and therapeutic methods involving same
US20050090457A1 (en) * 2002-02-15 2005-04-28 N.V. Nutricia Method of treating mammals with genistein and/or genistein analogues
KR100542478B1 (ko) * 2002-08-28 2006-01-11 한경대학교 산학협력단 석류 유래 피토에스트로겐을 함유하는 건강기능식품
MXPA05002652A (es) * 2002-09-09 2006-04-28 Nestec Sa Composicion oralmente administrable para mejorar la calidad de la piel.
KR100520408B1 (ko) * 2003-03-25 2005-10-10 주식회사 태평양 비만개선용 조성물
WO2004105517A1 (en) * 2003-05-27 2004-12-09 Dsm Ip Assets B.V. Novel nutraceutical compositions and use thereof
JP2005187454A (ja) * 2003-12-05 2005-07-14 Sankyo Co Ltd ビタミンｅ含有ｌｄｌ低下剤及び／又は動脈硬化抑制剤組成物
JP2007519678A (ja) * 2004-01-28 2007-07-19 ネステク ソシエテ アノニム 皮膚状態を改良しそして皮膚病を予防するための栄養組成物
CN1842327B (zh) * 2004-02-03 2011-05-11 株式会社红豆杉 将源于云南红豆杉的异紫杉脂素作为成分的骨质疏松症预防、治疗药
CA2559974C (en) * 2004-03-17 2012-08-14 Nestec S.A. Compositions and methods for reducing or preventing obesity
CN100351248C (zh) * 2004-07-05 2007-11-28 南京大学 染料木素衍生物及其制法和用途
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
DE102004060314A1 (de) * 2004-12-08 2006-08-31 Beiersdorf Ag Wirkstoffkombinationen aus einem oder mehreren Isoflavonoiden und Carnitin und/oder einem oder mehreren Acyl-Carnitinen
BRPI0519642A8 (pt) 2004-12-29 2017-10-03 Hill´S Pet Nutrition Inc Método para inibir um declínio em aprendizagem e/ou memória, kit apropriado para administrar um ou mais antioxidantes a um animal, meio para transmitir informação, e, uso de uma composição
AU2005323934A1 (en) * 2005-01-10 2006-07-13 Hormos Medical Ltd The use of a lignan for the manufacture of a composition for preventing or alleviating of symptoms relating to estrogen deficiency
SG162836A1 (en) * 2005-07-08 2010-07-29 Sigma Tau Ind Farmaceuti Use of a combination comprising l-carnitine or alkanoyl l-carnitine, lipid solubl benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases
CN101262780B (zh) 2005-07-14 2013-04-24 希尔氏宠物营养品公司 一种延长动物生命的方法
CN1939534B (zh) * 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
JP2009511523A (ja) * 2005-10-14 2009-03-19 ディーエスエム アイピー アセッツ ビー．ブイ． レスベラトロールを含むニュートラシューティカル組成物の新規な使用
RU2420091C2 (ru) * 2005-11-02 2011-06-10 Нестек С.А. Изофлавоновая композиция для снижения накопления телесного жира у млекопитающего мужского пола, ее применение, способ снижения накопления жира
WO2007099432A2 (en) 2006-02-28 2007-09-07 Council Of Scientific And Industrial Research Pharmaceutical composition containing butea isoflavones for the prevention /treatment of bone disorders and a process for the preparation thereof
CA2640575C (en) * 2006-02-28 2016-05-17 Nestec S.A. Compositions and methods for inducing bone growth and inhibiting bone loss
EP2004160B1 (en) * 2006-04-12 2012-09-19 Unilever PLC Oral composition with an antiageing effect on the skin
US20090286872A1 (en) * 2006-04-12 2009-11-19 John Casey Oral Composition Comprising Dha and Genistein for Enchancing Skin Properties
WO2007116027A1 (en) * 2006-04-12 2007-10-18 Unilever Plc Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin
US20080108696A1 (en) * 2006-08-02 2008-05-08 Brinton Roberta D Phytoestrogenic Formulations for Alleviation or Prevention of Neurodegenerative Diseases
US8680140B2 (en) * 2006-08-02 2014-03-25 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms
WO2008100560A2 (en) * 2007-02-14 2008-08-21 University Of Southern California Estrogen receptor modulators, associated pharmaceutical compositions and methods of use
AU2009292555B2 (en) * 2008-09-10 2014-05-29 AGC Inc. Novel prostaglandin I2 derivative
US20110091435A1 (en) * 2008-10-24 2011-04-21 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of hair loss
BRPI0921679A2 (pt) * 2008-11-11 2016-02-16 Sigma Tau Ind Farmaceuti composto útil para tratar celulite
KR101158856B1 (ko) 2009-05-12 2012-06-25 한국생명공학연구원 콩잎 추출물 또는 이의 분획물을 유효성분으로 함유하는 비만, 고지혈증, 동맥경화, 지방간, 당뇨 또는 대사증후군의 예방 또는 치료용 조성물
ES2593229T3 (es) * 2010-03-08 2016-12-07 Kaken Pharmaceutical Co., Ltd. Nuevo agonista de EP4
CN102939084A (zh) * 2010-06-16 2013-02-20 希格马托制药工业公司 在用于增加神经组织的神经发生的方法中使用的乙酰基-肉碱
WO2012011572A1 (ja) * 2010-07-23 2012-01-26 国立大学法人大阪大学 拡張不全型心不全治療薬
IT201700116392A1 (it) * 2018-04-03 2019-10-03 Composizione per somministrazione orale aventi benefico effetto sulla salute della donna in menopausa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1275434B (it) * 1995-05-19 1997-08-07 Farmila Farma Milano Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
US5702752A (en) * 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
US6139872A (en) * 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
AU6141498A (en) * 1997-02-04 1998-08-25 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases

Also Published As

Publication number Publication date
DE69904172T2 (de) 2003-08-28
HU224957B1 (en) 2006-04-28
CA2334875A1 (en) 1999-12-29
CA2334875C (en) 2009-05-12
AU4390999A (en) 2000-01-10
DE69904172D1 (de) 2003-01-09
AU755272B2 (en) 2002-12-05
NO20006431D0 (no) 2000-12-15
ITRM980417A1 (it) 1999-12-23
ES2188177T3 (es) 2003-06-16
TNSN99132A1 (fr) 2005-11-10
EE200000741A (et) 2002-04-15
WO1999066913A2 (en) 1999-12-29
AR018924A1 (es) 2001-12-12
EP1089742A2 (en) 2001-04-11
IT1299191B1 (it) 2000-02-29
KR20010071541A (ko) 2001-07-28
ATE228367T1 (de) 2002-12-15
IS5764A (is) 2000-12-08
CN1306434A (zh) 2001-08-01
MA26655A1 (fr) 2004-12-20
PL345030A1 (en) 2001-11-19
US6335038B1 (en) 2002-01-01
EP1089742B1 (en) 2002-11-27
SK19292000A3 (sk) 2001-08-06
WO1999066913A3 (en) 2000-04-20
BR9911440A (pt) 2001-03-20
HUP0102879A3 (en) 2002-12-28
PT1089742E (pt) 2003-04-30
IL140163A0 (en) 2002-02-10
PL192118B1 (pl) 2006-09-29
JP2002518437A (ja) 2002-06-25
NZ508877A (en) 2002-09-27
ITRM980417A0 (it) 1998-06-23
HUP0102879A2 (hu) 2002-03-28
JP4430233B2 (ja) 2010-03-10
DK1089742T3 (da) 2003-03-24
TR200003735T2 (tr) 2001-03-21

Similar Documents

Publication Publication Date Title
NO20006431L (no) Sammensetning for å forhindre og/eller behandle osteoporose og forandringer på grunn av menopausalsyndrom
WO2000011968A8 (en) ANTIOXIDANT COMPOSITION COMPRISING ACETYL L-CARNITINE AND α-LIPOIC ACID
DK1064009T3 (da) Anvendelse af ekstrakter af irisplanter og Cimicifuga racemosa og tectorigenin som estrogenagtigt organselektivt lægemiddel uden uterotrop virkning
NO20006430L (no) Neurobeskyttende sammensetning for forhindring og/eller behandling av nerve- og atferdsforandringer på grunn av angsttilstander eller depresjoner
BR0109912A (pt) Novas combinações antelmìnticas
CA2287965A1 (en) Treatment or prevention of menopausal symptoms and osteoporosis
NO20021640L (no) Sammensetning til forebygging og/eller behandling av kretslöpsykdommer som omfatter derivater av L-karnitin ogekstrakter av Gingo biloba
TR200003737T1 (tr) Diyet takviyesi ya da ilaç olarak kullanılan bileşim
WO2000007581A3 (en) Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid
AU5634500A (en) Dietary calcium as a supplement to vitamin d compound treatment of multiple sclerosis
NO20013787L (no) Soyaekstrakt som inneholder lipider, fremgangsmåte for dets fremstilling og farmasöytiske og kosmetiske blandinger
WO2000000183A3 (en) Antioxidant, cytostatic and sustained energy composition which ameliorates the metabolic utilization of glucose comprising acetyl-l-carnitine and a catechin
TR200101344T2 (tr) Propionil L-karnitinden ve bir flavonoid'den oluşan antioksidan bileşim
ATE239504T1 (de) Zusammensetzung zur vorbeugung und/oder behandlung von störungen aufgrund von abnormalen fettstoffmetabolismus, enthaltend l-carnitin und chitosan
Tejada et al. Quercetin effects on exercise induced oxidative stress and inflammation
NO952601L (no) Oligonukleotider for inhibering av ekspresjon av isoprenylprotein-transferaser
ATE339962T1 (de) Zubereitungen zur behandlung von lupus
TR200200015T2 (tr) L-Karnitin ve türevleri ile crataegus ekstreleri içeren kardiyoaktif bileşim
BR0309055A (pt) Uso combinado de l-carnitina, acetil l-carnitina e propionil l-carnitina para o tratamento da oligoastenoteratospermia
KR940003550A (ko) 노인성 치매 예방 및 치료방법
MX9709684A (es) Uso de derivados de vitamina d4 para tratamiento de trastornos de la piel.
HUP9902840A2 (hu) Lektin alkalmazása daganatos megbetegedések kezelésére alkalmas gyógyszerkészítmények előállítására

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application